IRS-19, spray 20 ml

Enhancing specific and nonspecific immunity.

When sprayed, a fine aerosol is formed, which covers the nasal mucosa, resulting in rapid development of a local immune response. Specific protection is due to locally formed antibodies of the class of secretory immunoglobulins type A (IgA) which prevent the fixation and reproduction of infectious agents on the mucosa.

Nonspecific immunoprotection is manifested by increased phagocytic activity of macrophages, increased content of lysozyme.

Indications

Active ingredient

Composition

Active ingredients:

Bacterial lysates 43.27 ml,

including Streptococcus pneumoniae type I1.11 ml

Streptococcus pneumoniae type II1.11 ml

Streptococcus pneumoniae type III1.11 ml

Streptococcus pneumoniae type V1.11 ml

Streptococcus pneumoniae type VIII1.11 ml

Streptococcus pneumoniae type XII1.11 ml

Haemophilus influenzae type B3.33 ml

Klebsiella pneumoniae ss pneumoniae6.66 ml

Staphylococcus aureus ss aureus9.99 ml

Acinetobacter calcoaceticus3.33 ml

Moraxella catarrhalis2.22 ml

Neisseria subflava2.22 ml

Neisseria perflava2.22 ml

Streptococcus pyogenes group A1.66 ml

Streptococcus dysgalactiae group C1.66 ml

Enterococcus faecium0.83 ml

Enterococcus faecalis0.83 ml

Streptococcus group G1.66 mg

Auxiliary substances:

Glycine – 4.25 g,

Mertiolate sodium – not more than 1.2 mg,

Nerol-based fragrance (linalool, alpha-terpineol, geraniol, methylanthranilate, limonene, geranyl acetate, linalyl acetate, diethylene glycol monoethyl ether, phenylethyl alcohol) – 12.5 mg,

Purified water – up to 100 ml.

How to take, the dosage

The drug is administered intranasally by aerosol administration of 1 dose (1 dose = 1 short press of the sprayer).

For preventive purposes, adults and children from 3 months of age administer 1 dose of the drug in each nostril twice a day for 2 weeks (it is recommended to start the course of treatment 2-3 weeks before the expected rise in the disease rate).

For treatment of acute and chronic upper respiratory tract and bronchial diseases in children aged 3 months to 3 years old 1 dose of the drug is given into each nostril 2 times a day after preliminary clearing of mucous discharge until disappearance of infection symptoms; children over 3 years old and adults – 1 dose of the drug in each nostril from 2 to 5 times a day until disappearance of infection symptoms.

For restoration of local immunity after influenza and other respiratory viral infections children and adults are prescribed 1 dose of the drug in each nostril 2 times daily for 2 weeks.

In preparation for elective surgery and in the postoperative period for adults and children 1 dose of the drug is given into each nostril 2 times a day for 2 weeks (one week before the planned surgery it is recommended to start the treatment).

Principles of Use

In order for the aerosol can to function properly, the nozzle should be placed on the can, centered and gently pressed down without effort. The device is then ready to use.

The can must be held in a fully upright position with the patient’s head still upright when spraying.

If the bottle is tilted while spraying, the propellant will leak within seconds and the device will be unusable.

If the product is used regularly, it is not recommended to remove the tip from the bottle.

If left unused for an extended period of time, the drop of liquid can evaporate and create crystals that clog the nozzle outlet. This most often happens when the tip is removed and placed in the package with the tip down next to the bottle without first rinsing and drying it. If the nozzle is clogged, several pushes should be made in succession to allow the liquid to pass under overpressure; if no effect, immerse the nozzle in warm water for a few minutes.

Interaction

There are no known cases of negative interaction of IRS 19 with other medicinal products.

In case of clinical symptoms of bacterial infection, antibiotics may be prescribed with continued use of IRS 19.

Special Instructions

In the beginning of treatment, reactions such as sneezing and increased nasal discharge may occur. These are usually transient. If these reactions become severe, the frequency of administration of the drug should be reduced or it should be stopped.

In the beginning of treatment, in rare cases, the body temperature may increase ≥39 ° C. In this case the drug should be discontinued. However, this state should be distinguished from the fever accompanied by malaise, which may be associated with the development of ENT diseases.

In case of clinical symptoms of bacterial infection, systemic antibiotics should be considered.

If IRS 19 is prescribed to patients with bronchial asthma, the number of attacks may increase. In this case, we recommend stopping treatment and not taking this class of medications in the future.

Indications on driving and operating machinery

IrS 19 has no effect on the psychomotor functions associated with driving or operating machinery.

Synopsis

Contraindications

Side effects

Dermatological reactions: rare – erythema-like and eczema-like reactions; in single cases – thrombocytopenic purpura and erythema nodosum.

Allergic reactions: rarely – urticaria, angioedema.

Respiratory system: rare – asthma attacks and cough, at the beginning of treatment – rhinopharyngitis, sinusitis, laryngitis, bronchitis.

The digestive system: rarely (at the beginning of treatment) – nausea, vomiting, abdominal pain, diarrhea.

Others: rare (at the beginning of treatment) – increase in body temperature (>39 ° C) for no apparent reason.

The side effects may or may not be related to the action of the drug. If the above symptoms occur, it is recommended to see a doctor.

Overdose

Pregnancy use

Similarities